The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Sanofi SA

NYSE: SNY
Last

(U.S.) $42.63

Today's change+0.03 +0.07%
Updated July 29 4:02 PM EDT. Delayed by at least 15 minutes.
 

Sanofi SA

NYSE: SNY
Last

(U.S.) $42.63

Today's change+0.03 +0.07%
Updated July 29 4:02 PM EDT. Delayed by at least 15 minutes.

Sanofi SA up slightly

Sanofi SA closed up just (U.S.)$0.03 Friday to (U.S.)$42.63. Over the last five days, shares have gained 0.76%, but are currently unchanged over the last year to date. Shares have underperformed the S&P 500 by 22.10% during the last year.

Key company metrics

  • Open(U.S.) $41.64
  • Previous close(U.S.) $42.60
  • High(U.S.) $42.74
  • Low(U.S.) $41.62
  • Bid / Ask(U.S.) $41.51 / (U.S.) $42.70
  • YTD % change-0.047%
  • Volume2,028,524
  • Average volume (10-day)1,667,175
  • Average volume (1-month)3,070,962
  • Average volume (3-month)2,336,237
  • 52-week range(U.S.) $37.41 to (U.S.) $54.98
  • Beta0.99
  • Trailing P/E22.83×
  • P/E 1 year forward10.41×
  • Forward PEG1.41×
  • Indicated annual dividend(U.S.) $1.66
  • Dividend yield3.90%
  • Trailing EPS(U.S.) $1.87
Updated July 29 4:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+12.82%

Based on its net profit margin of 12.82%, Sanofi SA is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.21%Sector:Industry:

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue7,92834,8619,68018,351
Total other revenue--------
Total revenue7,92834,8619,68018,351
Gross profit5,48123,9426,68212,627
Total cost of revenue2,44710,9192,9985,724
Total operating expense6,77429,2877,72514,957
Selling / general / administrative2,2129,3822,4615,086
Research & development1,2355,0821,3552,489
Depreciation / amortization4442,1375981,229
Interest expense (income), net operating--------
Unusual expense (income)5001,612267413
Other operating expenses, total-641554616
Operating income1,1545,5741,9553,394
Interest income (expense), net non-operating---246---132
Gain (loss) on sale of assets--------
Other--------
Income before tax1,0375,2431,8503,189
Income after tax9204,5341,5782,450
Income tax, total117709272739
Net income1,0874,2871,6282,325
Total adjustments to net income--------
Net income before extra. items9874,4111,6282,325
Minority interest-26-101-23-59
Equity in affiliates93-2273-66
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items9874,4111,6282,325
Inc. avail. to common incl. extra. items1,0874,2871,6282,325
Diluted net income1,0874,2921,6282,327
Dilution adjustment--5--2
Diluted weighted average shares1,2881,3211,3131,322
Diluted EPS excluding extraordinary itemsvalue per share0.773.341.241.76
Dividends per sharevalue per share0.002.930.000.00
Diluted normalized EPSvalue per share1.114.401.412.00